First page of the Philanthropy People archive

There is still hope for patients with genetic disorders; Scott Rocklage

Posted by Benjamin on May 9, 2018 with No Comments

Dr.Scott Rocklage enjoys a three-decade experience in healthcare management industry. His work as a doctor can is felt across the healthcare industry. Scott in alumnus of the University of California and Massachusetts Institute of Technology where he earned a B.S. in Chemistry and a Ph.D. in Chemistry. It when he was pursuing his doctorate that he got to chance to research at Richard Schrock’s laboratory. Richard Schrock is a Noble prize winner. His education has greatly influenced his career. Today, he works a managing partner for 5am Ventures, a position he assumed a year later after joining the venture.

Prior to joining 5AM ventures, Rocklage served as the CEO and president for both Nycomed Salutar and Cubist Pharmaceuticals Inc. in the years between 1990-1994 and 1994-2003 respectively. During his reign at 5am ventures, the company has experienced tremendous success over the last one decade. It has achieved 3 FDA drug approves (Omniscan™, Teslascan®, and Cubicin®) and numerous drug clinical trials. While still working at the company, Scott has served in other capacities as chairman of the Board, at Achaogen for a decade since 2004, and Cidara Therapeutics in 2013 till to date. Besides, he became chairman at Novira Therapeutics and also CEO for Epirus Biopharmaceuticals in 2016.

Additionally, he worked as the director at Pulmatrix, Inc. Currently, Scott has managed to patent over 30 drugs and has done more than 100 publications. In January 2018, Scott founded Expansion Therapeutics, an institute that will focus on research and curing genetic disorders. With the help from a number of ventures like Kleiner Perkins, 5AM Ventures, RA Capital Management, Sanofi Ventures, Alexandria Venture Investments and Novartis Venture Fund Scott firmly believes that soon they shall be able to find a cure for different kinds of muscular dystrophy. The defect occurs when production of some RNAs reaches toxic levels in the cell, eventually causing t damages to most body systems. In a statement, Rocklage stated that Dr. Disney would be leading the research team. Learn more: https://www.linkedin.com/in/scott-rocklage-66aa7a12a

Dr. Disney is positive about his team, and he is clear that the endeavor is about giving patients an option.